OTTAWA, Ontario & NEW YORK--(BUSINESS WIRE)--Turnstone Biologics, a clinical-stage immuno-oncology company developing the next generation of oncolytic viral therapies, today announced its presentation at the upcoming investor conference:
-
2018 Wedbush PacGrow Healthcare Conference
Date: Tuesday, August 14, 2018
Time: 3:05 p.m. ET
Presenter: Sammy Farah, Ph.D., President and Chief Executive Officer
About Turnstone Biologics
Turnstone Biologics is a clinical-stage, immuno-oncology company developing the next-generation of oncolytic viral immunotherapies for patients with a broad range of solid tumors. The company's Maraba (MG1) oncolytic virus platform is the first to combine the tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual's own immune system to attack the tumor, with the goal of preventing recurrence and delivering a cure. Turnstone is advancing a robust pipeline of clinical and preclinical programs. Turnstone has initiated multiple Phase I/II clinical trials with medicines targeting MAGEA3-expressing tumors, such as non-small cell lung cancer, and HPV positive tumors, such as cervical and head and neck cancers, and by 2019 expects to have multiple additional therapies in the clinic. In 2017, Turnstone executed the largest strategic partnership in the oncolytic virus field with AbbVie, and was named a FierceBiotech “Fierce 15” company. The Company’s lead investors include Versant Ventures, OrbiMed, F-Prime Capital Partners and FACIT. For more information, please visit http://turnstonebio.com/.
